What is forming beneath the surface of today's signals is a bifurcation — the ecosystem is sorting itself into substances that can survive regulatory scrutiny and those that will require a decade of analog development to do so. Psilocybin is quietly becoming the lead horse. Its safety-efficacy profile, while not perfect, grows cleaner relative to MDMA's rocky NDA journey and ibogaine's cardiac liability. The fluoxetine interaction paper is a complication, not a disqualification — and FDA is more likely to issue formal washout-period guidance on psychedelic-SSRI protocols before end of 2026 than to pause psilocybin development altogether. That guidance, when it arrives, will function as a de facto institutional acknowledgment that psychedelics are entering the pharmacopeia. The ibogaine story is migrating from clinical programs into analog development: DemeRx or a comparable sponsor will pivot toward oxa-noribogaine within 18 months. The ketamine clinic expansion continues its own trajectory — rapid, underregulated, and generating the kind of diversion patterns that historically precede a DEA enforcement sweep. That sweep, in at least five states, is now more probable than not before year's end.

The people inside these signals are holding specific kinds of waiting. There are veterans who have already traveled to Mexico or Portugal for ibogaine treatment, who returned changed, who now watch the American regulatory apparatus debate cardiac screening protocols — and what they feel is not impatience exactly, but a kind of grief at the distance between what they know in their bodies and what the institutions require before they will believe it. There are patients enrolled in psilocybin trials who stopped their SSRIs months ago to meet washout requirements, living in the gap between the medication they left and the treatment they are waiting for. There are ketamine clinic patients who found something real in those sessions, who don't know that the clinic they trust may be operating in a DEA crosshair. These are not abstractions. The regulatory calendar and the human calendar are running at different speeds, and the people caught between them are paying that difference in suffering.

OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.

Ibogaine's QT prolongation liability is well-documented and increasingly cited in regulatory correspondence, creating strong sponsor incentive to pivot to cleaner analogs. Oxa-noribogaine demonstrates comparable mechanistic activity (mPFC glutamatergic modulation, kappa-opioid antagonism) without the hERG channel interference responsible for cardiac risk. DemeRx or a successor sponsor has preclinical packages sufficient to file an IND. Eighteen months from April 2026 is achievable for IND submission and Phase 1 initiation if preclinical tox is complete. Confidence set at 0.62 reflecting genuine uncertainty about sponsor identity, funding, and IND timeline slippage.